President Trump has signed an executive order aimed at forcing down the price Americans pay for prescription drugs, and the administration’s claims about its reach are sweeping. The order embraces a “most favored nation” approach, which would tie U.S. drug prices to the lower prices that manufacturers charge in other wealthy countries. Officials say the policy could reduce some prices by anywhere from 30 percent to 80 percent, and it takes aim at the pharmacy middlemen who sit between drugmakers and patients. For retirees who spend a large and rising share of their income on medication, the promise is significant, but so is the gap between what an order announces and what actually reaches the pharmacy counter.
The core idea is straightforward. Americans routinely pay far more for the same medicines than patients in Europe, Canada, or Japan, and the order seeks to erase that gap by benchmarking U.S. prices to the lowest paid abroad. Whether that goal translates into real savings depends on rules and negotiations that are still unfolding.
How “most favored nation” pricing is supposed to work
Under a most-favored-nation model, the price paid in the United States would be pegged to the lowest price a drugmaker accepts in a comparable developed country, rather than being set by the domestic market alone. The executive order delivering most-favored-nation pricing directs federal health officials to pursue that benchmark and to press manufacturers to bring U.S. prices in line with foreign ones. The administration argues that drugmakers have long charged American patients more to subsidize lower prices elsewhere, and that anchoring to an international standard would end that arrangement.
The 30-to-80 percent range the administration cites reflects how large the current gap is for certain drugs. But that figure is a projection of what could happen if the policy is fully implemented and manufacturers comply, not a discount that is already showing up on receipts.
Free retirement updates: Enrollment and claim windows come and go, and missing one can cost real money. The free Retirement Shield newsletter stays ahead of the deadlines that matter. Sign up free.
The pharmacy middlemen in the crosshairs
The order also targets pharmacy benefit managers, the intermediaries that negotiate drug coverage on behalf of insurers and employers. These companies decide which drugs a plan covers, at what cost, and pocket a portion of the rebates and fees along the way. Critics across the political spectrum have argued that this opaque middle layer inflates costs and steers patients toward pricier options, and the order signals an intent to squeeze their role in the supply chain. Reducing what these intermediaries extract is, in theory, another route to lower out-of-pocket costs, though changing entrenched industry practices is difficult and slow.
For a retiree, the appeal is obvious: less money captured by middlemen could mean lower copays. The complication is that these arrangements are deeply embedded in how insurance and Medicare drug plans are built, so any shift takes time and detailed regulation to accomplish.
Why the savings are not guaranteed yet
An executive order sets a direction; it does not by itself rewrite drug prices. The actual results depend on rules being drafted by the Department of Health and Human Services and the Centers for Medicare and Medicaid Services, on target prices being defined, and in many cases on voluntary agreements with individual drug companies. Several large manufacturers have since entered negotiations and struck deals with the administration to lower certain prices, which suggests movement, but the scope of those agreements and how much they lower real-world costs for ordinary patients is still being worked out. Past attempts at international-reference pricing have also faced legal challenges from the pharmaceutical industry, another reason the timeline and final reach remain uncertain.
That is why the honest framing is that the order says it will cut prices, and the administration projects large reductions, while the concrete savings are still being built through rulemaking and dealmaking rather than delivered in full today.
What it could mean for a retiree’s medicine budget
For older Americans, prescription costs are among the most stubborn line items in a fixed budget, and even partial relief would matter. Medicare’s separate drug-benefit changes have already capped annual out-of-pocket spending for Part D enrollees, and a most-favored-nation policy layered on top could, if realized, push certain list prices lower and ease costs further. The key for beneficiaries is to watch for changes that actually reach their own plan, which will show up in formularies, negotiated prices, and annual plan notices rather than in headlines about the order itself. Comparing Part D or Advantage drug coverage each fall during open enrollment remains the most reliable way to capture whatever savings do materialize.
Staying grounded against hype and scams
Big promises about drug savings can also become bait. Retirees should be cautious of callers, texts, or ads claiming to offer access to “new government drug discounts” that require sharing a Medicare number, Social Security number, or payment to enroll. Legitimate price changes flow through Medicare, insurers, and pharmacies, not through unsolicited sign-up offers. As coverage of the pricing order has noted, the policy’s ultimate impact will be measured in the rules that follow, so the sensible posture is patience: track how the changes affect an actual plan, verify any drug-savings offer through official Medicare channels, and keep shopping coverage annually rather than assuming a single order has already delivered the full discount.
This article was researched and drafted with the assistance of AI and reviewed by The Financial Wire editorial team.
More Financial Reading
- Adding someone to your bank account: tax traps and smart moves
- Bank statements: how long to keep them and when to toss them
David M. Keller is a finance writer based in Columbus, Ohio, covering personal finance and consumer-focused economic topics. He earned his degree in journalism from Ohio University and began his career reporting on local business and economic trends for a regional media outlet. Since then, he has contributed to a variety of online publications, focusing on clear, practical coverage of topics such as cost of living, debt, and everyday financial decision-making.
